An accurate tool enabling early diagnosis of hepatocellular carcinoma (HCC) is clinically important, given that early detection of HCC markedly improves survival. We aimed to investigate the molecular markers underlying early progression of HCC that can be detected in precancerous lesions. We designed a gene selection strategy to identify potential driver genes by integrative analysis of transcriptome and clinicopathological data of human multistage HCC tissues, including precancerous lesions, low-and high-grade dysplastic nodules. The gene selection process was guided by detecting the selected molecules in both HCC and precancerous lesion. Using various computational approaches, we selected 10 gene elements as a candidate and, through immunohistochemical staining, showed that barrier to autointegration factor 1 (BANF1), procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3), and splicing factor 3b subunit 4 (SF3B4) are HCC decision markers with superior capability to diagnose early-stage HCC in a large cohort of HCC patients, as compared to the currently popular trio of HCC diagnostic markers: glypican 3, glutamine synthetase, and heat-shock protein 70. Targeted inactivation of BANF1, PLOD3, and SF3B4 inhibits in vitro and in vivo liver tumorigenesis by selectively modulating epithelial-mesenchymal transition and cell-cycle proteins. Treatment of nanoparticles containing small-interfering RNAs of the three genes suppressed liver tumor incidence as well as tumor growth rates in a spontaneous mouse HCC model. We also demonstrated that SF3B4 overexpression triggers SF3b complex to splice tumor suppressor KLF4 transcript to nonfunctional skipped exon transcripts. This contributes to malignant transformation and growth of hepatocyte through transcriptional inactivation of p27
H epatocellular carcinoma (HCC) is the second-leading cause of cancer-related death worldwide. HCC is one of the few cancers that have increasing in incidence recently.
(1) The primary curative treatment for HCC is surgical resection with a minority of patients diagnosed at early stages, when curative treatments are feasible. Resection and percutaneous ablation are hampered by a recurrence rate up to 70% at 5 years, which is closely linked to survival. (2) As with other cancers, HCC is characterized by an obvious multistep process of tumor progression. (3) In the initial stage, the damaged liver tissues evolve into small nodular hypercellular lesions called dysplastic nodules (DNs). These precancerous lesions develop into early HCC (eHCC), defined as small, welldifferentiated HCC of vaguely nodular type, and then into progressed HCC, characterized by a distinctly nodular appearance and frequent microvascular invasion. (4) On the basis of current knowledge of multistep hepatocarcinogenesis (HCG), high-risk patients are closely followed up, and increasing numbers of small equivocal lesions are detected by diagnostic imaging. Ultrasound-guided needle biopsy is performed on such lesions. If they are diagnosed histologically as cancer, they are treated. However, eHCC shows minimum atypia and lacks definite invasive or destructive growth. (5) Therefore, it is often difficult, even for the hepatopathologist, to distinguish regenerative nodules, precancerous lesions, and early-stage HCCs. For these reasons, the discovery of an objective molecular marker that will help standardize histological diagnosis of early-stage HCC and lead to appropriate treatment is eagerly anticipated. In addition, identification of biomarkers correlating with the accurate diagnosis of HCC may help identify precancerous lesions most likely to progress to overt HCC and determine legions that are surgically resectable, and so could guide clinicians in designing the operative range of HCC patients. The identification of additional molecular markers predicting the potential for the development of HCC in precancerous lesion could help identify patients at risk of recurrence after surgical resection.
In this study, we aimed to establish a gene selection strategy to identify potential driver genes by integrating clinicopathological and gene expression data of multistage human HCC tissues defined by hepatopathologists. This allowed the identification of 10 candidate early-stage HCC driver genes. Further clinical and experimental efforts suggested that among the 10 candidate driver genes, barrier to autointegration factor 1 (BANF1), procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (PLOD3), and splicing factor 3b subunit 4 (SF3B4) were able to indicate HCC in the precancerous lesion, with superior capability to diagnose eHCC in a large cohort of HCC patients, as compared to the currently popular trio of HCC diagnostic markers (conventional markers; CMs): glypican 3 (GPC3), glutamine synthetase (GS), and heat-shock protein 70 (HSP70). Aberrant overexpression of SF3B4 was shown to produce hyperactivity of the spliceosome complex, accelerating the production of alternative splicing variants of the Kruppel-like factor 4 (KLF4) tumor suppressor to nonfunctional skipped exon transcripts, abolishing the function of KLF4 to disturb cell-cycle regulation by suppressing p27
Kip1 and epithelialmesenchymal transition (EMT) by enhancing Slug in HCC cells. Here, we suggest that the early-stage HCC diagnostic markers, BANF1, PLOD3, and SF3B4, contribute to early malignant transformation of hepatocytes in liver tumorigenesis, and are a promising target for molecular therapies of liver malignancies.
Materials and Methods

PATIENTS AND SPECIMENS
Three independent cohorts of patients with liver disease were involved in this study. Cohort 1 (107 snap-frozen tissues from 81 HCC patients) were used in gene expression analysis with human wholetranscriptome microarray, cohort 2 (546 tissues from 546 HCC patients) were used in immunohistochemistry (IHC) of tissue microarray (TMA), and cohort 3 (160 HCC full sections from 70 HCC patients) were used in an IHC study of the HCC full section (Supporting Fig. S1 ). Clinicopathological characteristic of patients in the three cohorts are detailed in Supporting  Table S1 . Progression-free survival was defined as the interval between the date of surgery and the date of diagnosis of any type of recurrence. Written informed consent was obtained from all subjects according to the Declaration of Helsinki, and the study was approved by the Institutional Review of Board (IRB) of the Songeui Campus of the Catholic University of Korea College of Medicine (IRB approval No: MC12EISI0106, MC12SNMI0184).
TMAs AND IHC
For the TMA construction, tumor regions of formalin-fixed, paraffin-embedded liver samples from cohort 2 (n 5 546) patients were mapped by a pathologist for scoring. Liver tissues were punched out of each block and placed into recipient paraffin blocks using a 0.6-mm-diameter stylet and cut into 5-mmthick sections. Sections were adhered to the slide by an adhesive tape-transfer method and ultraviolet irradiated to cross-link. To investigate the protein level of each biomarker, IHC staining was performed using the antibodies listed in Supporting Table S2 on TMA and full-section samples.
PUBLICLY AVAILABLE GENOMIC DATA ANALYSES
To recapitulate the expression level of HCC markers in HCC, data were obtained from The Cancer Genome Atlas liver hepatocellular carcinoma project (TCGA_ LIHC) and the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI) (Accession Numbers: GSE16757, GSE22058, GSE25097, GSE36376, GSE44106, GSE45436, GSE54236, GSE80861, and GSE93392). Level 3 mRNA expression data of TCGA_LIHC RNA-seq V2 were log2 transformed (log2 (RSEM11)) and used to assess the gene expression levels.
WESTERN BLOTTING ANALYSIS
Patient frozen tissue and cells were lysed in protein extraction buffer (50 mM of HEPES, 5 mM of ethylenediaminetetraacetic acid, 50 mM of NaCl, 1% Triton X-100, 50 mM of NaF, 10 mM of Na 2 P 2 O 7 , 1 mM of Na 3 VO 4 , and 100X Halt protease inhibitor cocktail). Lysates containing equal amounts of proteins were separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA). The blottings were blocked with a 5% skim milk solution and incubated with the respective antibodies listed in Supporting Table S2 . GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as loading control.
Other assays used in this study are described in the Supporting Information.
STATISTICAL ANALYSIS
Survival curves were plotted using the Kaplan-Meier product limit method, and significant differences between survival curves were determined using the logrank test. All experiments were performed at least three times, and all samples were analyzed in triplicate. Results are presented as mean 6 SD or SEM. The statistical significance of the difference between experimental groups was assessed by paired or unpaired Student t tests using GraphPad 7.0 software (GraphPad Software Inc.). Statistical significance was determined for P < 0.05. A chi-square test (two-sided) was used to determine associations between parameters.
Results
IDENTIFICATION OF POTENTIAL CANCER DECISION MARKERS IN PRECANCEROUS LESIONS
To identify gene expression signatures associated with overt HCC within precancerous lesion, we conducted a combined analysis of clinicopathological data and gene expression with the following unbiased strategies. First, whole-transcriptome expression microarrays were used to examine 107 human hepatic tissues that were diagnosed by hepatopathologists, including 13 normal liver (NL), 8 low-grade fibrosis of chronic hepatitis (LGCH), 12 high-grade fibrosis of chronic hepatitis (HGCH), 12 cirrhosis (CS), 11 low-grade DN (LGDN), 11 high-grade DN (HGDN), 5 eHCCs, and 35 HCCs comprising 9 Edmonson Grade 1 (G1), 12 G2, and 14 G3 (Supporting Fig.  S1 ). Hierarchical clustering analysis resulted in three distinct subclusters within the dendrogram: chronic liver disease (LGCH, HGCH, CS, and LGDN), early-stage HCCs (HGDN, eHCC, and G1), and overt HCCs (G2 and G3) clusters (Fig. 1A) . Reanalysis with LGDN, HGDN, eHCC, and G1 showed that LGDN was discerned with the early-stage HCCs (Fig. 1B) . These results indicate that HGDN is a feature of the beginning of early-stage HCC; such a precancerous lesion may be the starting point of driver gene activation, thereafter progressing favorably to overt HCC. Based on these results, we designed a gene selection strategy to identify gene sets anticipating potential HCC within precancerous lesion, HGDN. Each molecular signature from LGDN to G1 HCC was combined (LGDN vs. HGDN, LGDN vs. eHCC/G1 HCC, and HGDN vs. eHCC/G1 HCC). Of these 690 gene signatures, 85 gene elements were dissected as their expressions gradually increased by the progression from LGDN to overt HCC (Fig. 1C) . Next, to select molecules indicating HGDN that develops to overt HCC, comparison analysis of a receiver operating characteristic (ROC) curve was performed (Fig. 1D ). Of these 85 gene elements, 13 were exhibited significantly specific and sensitive as biomarkers showing >0.8 area under the curve (AUC; Supporting Table S3 ). Note that AUC values of three individual CM genes, GPC3 (GPC3), GLUL (GS), and HSPA1A (HSP70), exhibited relatively lower than that of 13 candidate gene elements in ROC curve analysis based on gene expression value. Expressions of 13 gene elements were then assessed in large cohorts of HCC patients available from TCGA_-LIHC and the NCBI GEO database. From this, three gene elements, ALKBH2, HSD3B7, and PARP10, were excluded because they were not consistently overexpressed (>1.5-fold) in different HCC patient cohort studies (<50% of six tested cohorts; Supporting Table  S4 ). We then observed overexpression of 10 candidate gene elements in HCC compared to nontumor from both TCGA_LIHC and our cohort 1 (GSE89377) data sets (Supporting Fig. S2A,B ). Note that all 10 genes were significantly overexpressed in HCC compared to nontumor in both 50-matched pairs and 371 HCCs data sets of TCGA_LIHC. Next, to validate protein overexpression of these 10 molecules in HCC compared to nontumor liver tissue (NT), IHC analysis was done using a TMA containing 546 HCCs (cohort 2, n 5 546: 140 G1, 297 G2, and 109 G3, respectively). Among 10 tested marker molecules, cytochrome C1 (CYC1), family with sequence similarity 83 member H (FAM83H), MAD3, and maternal 
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embryonic leucine zipper kinase (MELK) were not significantly overexpressed in HCC compared to adjacent NT (Fig. 1E) . After multivariate analysis of the cohort 2 study for the various clinicopathological parameters, we counted each clinicopathological score that achieves statistical significance in each category, then selected the three markers, BANF1, PLOD3, and SF3B4, because they achieved high score (46 clinicopathologic scores) in the multivariate analysis ( Table 1 ). Note that three CMs exhibited 24 clinicopathologic scores in the same analysis (Supporting Table S5 ).
VALIDATION OF BANF1, PLOD3, AND SF3B4 AS DECISION MARKER FOR HCC IN PRECANCEROUS LESIONS
To validate BANF1, PLOD3, and SF3B4 molecules as early-stage HCC decision markers in the precancerous lesions, IHC analysis was done using six full sections of eHCCs transitioning from HGDN. As expected, among the 10 tested markers, BANF1, PLOD3, and SF3B4 showed strong or moderate positive in eHCC and HGDN (36 of 6 full sections), whereas surrounding noncancerous lesions within regenerating nodules (RNs) were positive in only 1 case (Fig. 2A) . The remaining six markers showed no significant difference between eHCCs and RNs. The adopted panel of three CMs (GPC3, GS, and HSP70) is known to be helpful for discriminating eHCC from other neoplastic lesions, including DN, liver cell adenoma, and focal nodular hyperplasia.
(6) Therefore, we next performed comparative IHC analysis for three CMs and our novel markers (NMs; BANF1, PLOD3, and SF3B4) with 70 full sections including 55 earlystage HCCs and 105 RNs. The positive rate against more than 2 CMs (2(1)/3 CMs) in HCC was 50.9% (28 of 55), whereas the positive rate against more than 2 NMs (2(1)/3 NMs) in HCC was 72.7% (40 of 55; Fig. 2B ; Supporting Table S6 ). In contrast, the negative rate of CMs (1(1)/3 CMs) in HCC was 49.1% (27 of 55), whereas the negative rate of NMs (1(1)/3 NMs) was 27.3% (15 of 55). Notably, the positive rate of NMs in CMs negative HCC was 59.3% (16 of 27), whereas the positive rate of CMs in NMs negative HCC was 26.7% (4 of 15; Fig. 2C ). However, there was no significant difference in the negative rate between CMs and NMs in RNs (Fig. 2D) . Comparison analysis of ROC curves was performed to determine a better marker than the CMs (Supporting Table S7) . Notably, the combination of two sets (HSP70, GPC3, BANF1, and SF3B4) resulted in the most sensitive and specific early decision marker in precancerous lesion of HCC ( Fig. 2E ; Supporting Table S8 ). On the other hand, Kaplan-Meier survival curves of 546 HCC patients (cohort 2) showed that each of the progression-free survival rates of HCC patients with high expressed NM was significantly lower than that of patients with low expression level of NM, whereas differential expression of each CM was not associated with an HCC patient's survival (Supporting Fig. S3B ). We also noted that 2(1)/3 NMs exhibited significant association with poor progression-free survival of HCC patients, whereas a criterion of combined CMs and NMs was not associated with a patient's survival, suggesting NMs as earlystage drivers of HCC (Fig. 2F) .
BANF1, PLOD3, AND SF3B4 ARE OVEREXPRESSED IN HCC AND THEIR INACTIVATION ELICIT ANTI-TUMOR EFFECTS IN VITRO AND IN VIVO
Aberrant regulation of BANF1, PLOD3, and SF3B4 in HCC was confirmed with 50 matched pairs of HCC patients in the TCGA_LIHC data set and further validated with an additional set of 13 randomly selected matched pairs of HCC tissues by qRT-PCR (Fig. 3A) . BANF1, PLOD3, and SF3B4 were overexpressed in 912 (69%92%) of 13 HCCs compared with adjacent NTs. Western blotting analyses for seven pairs of eHCC with NL and 3 pairs of eHCC with adjacent DN and NL also showed marked overexpression of BANF1, PLOD3, and SF3B4 in eHCC (Fig.  3B) . Next, to generalize our observation, we recapitulated Banf1, Plod3, and Sf3b4 expression of chemically induced mouse and rat HCC models available from the GEO database. Banf1, Plod3, and Sf3b4 expressions in both mouse and rat models exhibited upregulation in adenomas (ADs), eHCCs, and advanced HCCs (aHCCs) compared to that of corresponding NLs (Fig. 3C) . In order to validate these results, we prepared H-ras transgenic mouse and DEN-induced rat HCC models and examined Banf1, Plod3, and Sf3b4 expressions by western blotting analysis. Banf1, Plod3, and Sf3b4 were markedly overexpressed in both mouse and rat HCC models (Fig. 3D) .
Next, to investigate biological functions of BANF1, PLOD3, and SF3B4 in HCG, knockdown of each gene was attempted by RNA interference (RNAi) and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure the cell growth rate. Also, bromodeoxyuridine (BrdU) incorporation and clonogenic assays were used to measure the rate of proliferation of SNU-449 HCC cells. Individual knockdown of BANF1, PLOD3, and SF3B4 significantly reduced SNU-449 cell growth and proliferation rates (Fig. 3E,F) . BANF1, PLOD3, and SF3B4 were also significantly associated with metastatic behavior in clinicopathological features of the HCC patients, such as angioinvasion and differentiation (Table 1) . Thus, to elucidate the role of these molecules in the malignant behavior of HCC cells, we performed in vitro motility and invasion assays. A modified Boyden chamber assay revealed that individual knockdown of BANF1, PLOD3, and SF3B4 significantly suppressed the serum-stimulated migratory and invasive responses of SNU-449 cells (Fig. 4A) . Similarly, a scratch wound healing assay also showed that each individual knockdown reduced serum-stimulated wound-healing efficacy of SNU-449 cells (Fig. 4B) . To gain further insight into the regulatory effect of these molecules on EMT in HCC cells, , and Sf3b4 in mouse (top: GSE93392) and rat (bottom: GSE44106) liver tissues, including NLs, ADs, eHCCs, and aHCCs. *P < 0.05; **P < 0.01; ***P < 0.001; unpaired t test. (D) Western blotting analysis of Banf1, Plod3, and Sf3b4 in Hras transgenic mouse (top) and DEN-induced rat HCC models (bottom). (E) Cell viability (left) and cell proliferation rate (right) of SNU-449 cell transfected with negative control siRNA (si-Cont) and siRNA of each marker gene (si-BANF1, si-PLOD3, and si-SF3B4) was determined using MTT assay and BrdU assay, respectively. ***P < 0.001; unpaired t test. (F) Clonogenic cell growth of SNU-449 cell transfected in parallel with (E) determined using clonogenic assay. **P < 0.01; ***P < 0.001; unpaired t test.
western blotting analysis was performed for the EMT regulatory proteins. N-cadherin, Fibronectin, Snail, and Slug, hallmarks of EMT, were markedly decreased in indicated gene knockdown cells, whereas Ecadherin, an epithelial marker, was increased in the same cells (Fig. 4C) . These results suggest that the metastatic potential of the BANF1, PLOD3, and SF3B4 molecules could be attributed to the selective regulation of EMT proteins in HCC cells. Next, to demonstrate whether individual knockdown of BANF1, PLOD3, and SF3B4 causes a tumor suppressive effect in vivo, we subcutaneously injected knockdown cells into athymic nude mice. Overall tumor growth rate and average volume at sacrifice were significantly reduced in individual knockdown (si-BANF1, si-PLOD3, and si-SF3B4) groups compared to a negative control (si-Cont) group. In addition, at 50 days postinoculation, tumors were detected in 6 of 10 mice injected with control cells, whereas tumors were observed in 12 of 10 mice injected with si-BANF1, si-PLOD3, and si-SF3B4 groups, respectively (Fig. 4D) . To investigate whether mouse Banf1, Plod3, and Sf3b4 molecules play a synergistic role in mouse HCG, expression plasmids of Banf1, Plod3, and Sf3b4 were added to the hydrodynamic transfection (HT) injection mixture (TAZ S89A 1HRAS
G12V
) and compared with that of an HT injection mixtureonly group (Supporting Fig. S4A ). Liver weight/body weight ratios of HT injection mixture with the Banf11 Plod31Sf3b4 group showed higher than that of the HT injection mixture only group (Supporting Fig.  S4B,C) . Total number of tumor mass in the Banf11-Plod31Sf3b4 adding group was 9, whereas in the HT injection mixture-only group it was 3 (Supporting Fig.  S4D ). This result indicates that overexpression of Banf1, Plod3, and Sf3b4 enhances tumorigenic potential of oncogenic RAS and TAZ in mouse HCG. We then investigated the cancer preventive effect of BANF1, PLOD3, and SF3B4 inhibition by delivery of smallinterfering RNAs (siRNAs) specific for these three molecules using nanoparticles (MPNs [MesoPorous Nanoparticles]) with ultra-large pores. (7) We prepared H-ras transgenic mice that spontaneously develop HCC from approximately 1015 weeks of age. To investigate the cancer-preventive effect of targeting Banf1, Plod3, and Sf3b4 in vivo, mice were intravenously injected with MPNs containing siRNAs specific for Banf1, Plod3, or Sf3b4 (MPNs1siRNAs) from 9 weeks of age, and compared with that of MPNs only (Supporting Fig. S5A-C; Fig. 4E ). HCC in mouse liver was detected using ultrasonography from 16 weeks of age until the time of sacrifice at 23 weeks of age. HCC was detectable at 17 weeks of age in the MPN group, in which 3 of 4 mice developed large and multiple HCCs, whereas HCC was detectable at 19 weeks of age in the MPNs1siRNAs group, in which 2 of 4 mice develop relatively small HCCs. Western blotting analysis confirmed the suppression of Banf1, Plod3, and Sf3b4 expression in mouse adjacent NLs in the MPNs1siRNAs group (Fig. 4F ).
SF3B4 INACTIVATION SUPPRESSES TUMORIGENIC POTENTIAL OF HCC
Alteration frequency of BANF1, PLOD3, and SF3B4 in TCGA_LIHC was assessed to investigate the clinical relevance of each molecule in HCC. One hundred forty-four cases (39%) of 371 HCC patients exhibited overexpression of BANF1, PLOD3, and/or SF3B4 genes (Supporting Fig. S6A ). Kaplan-Meier survival curves indicated that both overall survival (OS) and disease-free survival (DFS) rates of HCC patients with BANF1, PLOD3, and SF3B4 up-regulation was significantly lower than that of HCC patients with normal expression (OS, P 5 0.0012; DFS, P 5 0.0009; log-rank test; Supporting Fig. S6B ). Interestingly, among the three molecules, only the high expression of SF3B4 was significantly associated with poor prognosis in OS of HCC patients (Supporting Fig. S6C ). Furthermore, SF3B4 amplification significantly associated with poor prognosis in both OS and DFS of HCC patients, and SF3B4 amplification was significantly correlated with SF3B4 overexpression in TCGA_LIHC "CNV and RNA-Seq" set (n 5 357), (8) indicating a possible activating mechanism of the SF3B4 during HCG (Supporting Fig. S6D,E) . In addition, the analyses of relative gene copy number and mRNA expression for SF3B4 in randomly selected 20-matched pairs of human HCC tissues exhibited a significant positive correlation (r 5 0.54; P 5 0.014) between the gene expression and copy number amplification (Supporting Fig. S6F ).
SF3B4 is one of six subunits of the splicing factor 3b (SF3b) complex, which is an important protein complex in the U2 snRNP supercomplex. Analysis of the alteration frequency and gene expression of six subunits of SF3b complex in the TCGA_LIHC and GEO databases showed that only SF3B4 was amplified in gene copy and was aberrantly overexpressed in HCC (Fig.  5A,B) . Assessment of endogenous SF3B4 expression using qRT-PCR in 10 different liver cell lines, including two immortalized normal hepatic cell lines (L-02 and MIHA) and eight human HCC cell lines, revealed significant overexpression of SF3B4 in both mRNA and protein levels compared with MIHA cells (Fig. 5C ). In addition, we confirmed that targeted disruption of SF3B4 suppressed tumor cell growth, proliferation, migration, invasion, and wound healing efficacy in both SNU-449 and SNU-368 HCC cells (Supporting Fig.  S7A-D) . Western blotting analysis also confirmed that targeted disruption of SF3B4 elicited the suppression of N-cadherin, Fibronectin, Snail, and Slug and, simultaneously, derepression of E-cadherin in the same cells (Supporting Fig. S7E ).
Because mRNA and protein levels of SF3B4 were overexpressed in HCC, we next assessed the prognostic association of SF3B4 expression in a large cohort of 100 HCC patients (GSE16757). Genes with expression patterns that highly correlated with SF3B4 expression (n 5 342) were selected for cluster analysis (P < 0.001; r > 0.5 or r < 20.5). Patients were then divided into a SF3B4 high cluster (SF3B4_high) group or a SF3B4 low cluster (SF3B4_low) group. The Kaplan-Meier survival curves of patients with HCC indicated that the 5-year OS rate of patients with high SF3B4 expression was significantly lower than that of patients with low SF3B4 expression (P 5 0.014; log-rank test; Fig. 5D ). Next, to investigate the biological relevance of the SF3B4-associated gene signature, gene set enrichment analysis (GSEA) was performed to identify signaling pathways related to SF3B4-associated gene signature in The Molecular Signatures Database (MSigDB). (9) KEGG_CELL_ CYCLE was identified as a highly significant enriched gene set (Fig. 5E) . Consistent with these results, flow cytometry cell-cycle analysis indicated that SF3B4 knockdown led to a significant increase in the number of cells in the G1 phase with a concomitant decrease in the number of cells in the S phase and G2/M phase in the SNU-449 HCC cells, whereas that SF3B4 knockdown did not affect cell death processing (Fig. 5F , left panel; Supporting Fig. S7F ). Note that a similar result was obtained by the treatment with the SF3b complex inhibitor, Spliceostatin A (SSA), in the same cells. To clarify the role of SF3B4 in cell-cycle progression, SF3B4 knockdown and SSA-treated HCC cells were then treated with nocodazole. This nocodazole treatment synchronizes the cells in the G2/ M phase. (10) After release from nocodazole block, the proportions of cells in the G1 phase were determined by flow cytometry. Both SF3B4 knockdown and SSA treatment caused a significant increase of liver cancer cells in the G1 phase and delayed cellcycle transition, suggesting that the proliferative defect and/or growth retardation of liver cancer cells by SF3B4 inactivation, at least in part, is attributed to interference with the cell cycle (Fig. 5E , right panel; Supporting Fig. S8A ).
SF3B4 FUNCTIONS AS DRIVER OF HCC BY ABERRANT SPLICING ACTIVITY ON TUMOR SUPPRESSOR KLF4
To gain further insight into the biological roles of SF3B4 in HCG, SF3B4 knockdown was performed to investigate spliceosome activity. Both SF3B4 knockdown and SSA treatment suppressed the expression of vascular endothelial growth factor (VEGF), a representative molecule regulated by the SF3b complex, whereas the unspliced form of VEGF mRNA (VEGF pre-mRNA) was increased in HeLa and two HCC cell lines (Fig. 6A) . Note that both SF3B4 knockdown and SSA treatment also suppressed tumor cell growth of these two HCC cell lines (Supporting Fig. S8B ). Western blotting analysis for cell-cycle regulatory proteins showed that both SF3B4 knockdown and SSA treatment suppressed the expression of CDK4, CDK2, cyclin D1, and cyclin E and, simultaneously, induced p27
Kip1 in two HCC cell lines (Fig. 6B) . These results suggest that SF3B4 overexpression causes the suppression of the negative cell-cycle modulator, p27 Kip1 , and simultaneously induces the expression of its regulators, CDK4, CDK2, cyclin D1, and cyclin E, leading to hyperphosphorylation of pRb to accelerate cell-cycle transition of HCC cells.
Next, to investigate direct targets of SF3B4 in HCC cells, the NGS RNA sequencing (RNA-seq) data of the SF3B4 knockdown HepG2 cells available from the GEO database (GSE80861) were analyzed, and identified 3,182 gene elements as differentially expressed genes (DEGs) in SF3B4 knockdown cells (>1.5-fold). To identify alternative splicing (AS) events specific to SF3B4 knockdown, paired-end reads were mapped to the ENCODE (Encyclopedia of DNA Elements; https://www.encodeproject.org/) database and exon inclusion was quantified using the Multivariate Analysis of Transcript Splicing (MATS) analysis tool (Fig.  6C) . The analysis resulted in five different alternative splicing events: skipped exon (SE); retained intron (RI); alternative 3' splice site (A3SS); alternative 5' splice site (A5SS); and mutually exclusive exons (MXE). Combination of these two analyses with more than two AS events resulted in eight markedly derepressed gene elements in SF3B4 knockdown HepG2 cells (Supporting Fig. S9A ). To generalize this finding in HCC, expressions of these eight gene elements were recapitulated from the TCGA_LIHC data set. This verified four gene elements (GRIP, PLP1, KLF4, and KRT80) as candidate target genes for SF3B4 (Fig.  6D ). Among these, notably we found that only KLF4 was significantly derepressed by SF3B4 knockdown in all five tested HCC cell lines ( Fig. 6E; Supporting Fig.  S9B) . A significantly negative correlation with SF3B4 and KLF4 expression among the eight gene elements was also evident in HCC patients (Supporting Fig.  S9C,D) . These results indicate that SF3B4 knockdown caused recovery of, at least, wild-type (WT) KLF4 transcript expression and thereby exerted an antitumor growth effect on HCC cells. Indeed, quantitative visualization of alternative exon expression from RNA-seq data of matched pairs of HCCs (cohort 1) demonstrated the suppression of WT KLF4 transcript to yield nonfunctional SE transcript of KLF4 in HCC (Fig. 6F) .
To clarify that SF3B4 overexpression triggers SF3b complex to splice KLF4 transcript to nonfunctional SE transcript, SF3B4 knockdown and ectopic expression of KLF4 plasmid were performed in HCC cells, and then we measured SF3B4 regulatory molecules, Kip1 and Slug in the same cells. As expected, ectopic expression of KLF4 recapitulated the SF3B4 knockdown effect in the same cells (Fig. 7A) . Next, to investigate whether SF3B4 activation directly regulates p27 Kip1 and Slug expression through the KLF4 transcriptional activity in HCC cells, a luciferase reporter plasmid harboring p27
Kip1
-or Slug-promoter was constructed and transfected into SNU-449 cells, along with cotransfection with SF3B4-specific siRNA or KLF4 plasmid. The luciferase activity of the p27 Kip1 -promoter transfectant was significantly up-regulated in both SF3B4 knockdown and KLF4 overexpressing cells, whereas the luciferase activity of the Slug-promoter transfectant was significantly suppressed in the same cells (Fig. 7B) . We then observed that SF3B4 knockdown induced KLF4 WT transcript expression and simultaneously suppressed alternative splicing isoforms of KLF4, Liver-KLF4 iso1
, and Liver-KLF4 iso2 in two HCC cell lines (Fig. 7C, left) . Direct sequencing analysis revealed the generation of the two different types of SE transcripts from the WT KLF4 transcript (Fig. 7C, middle and right) . Last, to demonstrate that SF3B4 inactivation elicits a tumor-suppressive effect through the recovery of tumor suppressor KLF4 in vivo, we subcutaneously injected SF3B4 knockdown and KLF4 overexpressing cells into athymic nude mice. The overall tumor growth rate and average volume at sacrifice were significantly reduced in both SF3B4 knockdown and KLF4 overexpressing SNU-449 cells-injected mice (Fig. 7D) . In addition, immunoblotting analysis confirmed the induction of KLF4 in both SF3B4 knockdown and KLF4-expressing xenograft tissues (Fig. 7E) .
Discussion
Comprehensive characterization of the molecular alterations in precancerous lesions and the corresponding changes in the microenvironment associated with progression should hasten the development of biomarkers for early detection and risk stratification, as well as contributing to the realization of preventive interventions to reverse or delay the development of cancer. In contrast to the extensive body of research concerning profiling advanced stage tumors, few studies have comprehensively profiled the genomic alterations found in precancerous tissues. Thus, the largest obstacle impeding the understanding of cancer initiation and progression and development of early detection tools is the lack of systematic collection, annotation, and profiling of precancerous lesions. To overcome this issue, we performed gene expression profiling analysis with 107 human hepatic tissues comprising fresh normal liver, chronic hepatitis, cirrhosis, dysplastic nodules, and multistage HCCs that were diagnosed by hepatopathologists (Supporting Fig. S1 ; Supporting Table S1 ). The present results from the integrative analysis of the studies comprehensively profiling precancerous and early-stage HCC implicate BANF1, PLOD3, and SF3B4 as molecules indicating early-stage HCC in precancerous lesions. The performance of BANF1, PLOD3, and SF3B4 exceeded the conventional three-panel HCC diagnostic markers for diagnosing HCC in the large cohort of HCC patients ( Figs. 1 and 2 ).
An evolutionary model posits that a specific sequence of genomic events acquired over many years causes the transition from normal epithelium to invasive carcinoma. (11) Thus, having a complete catalog of driver genes for each tumor type is only the first step in understanding cancer progression. Many driver genes can frequently be altered within an advanced-stage tumor. However, the order with which the events occur can be difficult to ascertain. In this respect, we designed a gene selection strategy to identify gene sets in precancerous lesions that are continuously deregulated from precancerous to overt HCC. Using various computational approaches, we selected 10 gene elements as candidates and showed that BANF1, PLOD3, and SF3B4 are possible drivers of early-stage HCC.
The expression and function data of BANF1, PLOD3, and SF3B4 were closely correlated and all pointing to the same direction. Indeed, when we analyzed correlation of each BANF1, PLOD3, and SF3B4, expressions of all three genes were significantly related to one another (Supporting Fig. S10A ). Therefore, to clarify whether their expression is under a common regulatory signaling and mechanism or not, we performed network neighborhood analysis by "The cBio Cancer Genomics Portal." (12) Network neighborhood analysis of BANF1, PLOD3, and SF3B4 with phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling molecules showed that BANF1, PLOD3, and SF3B4 are located in the borderline or outside of the PI3K-AKT-mTOR signaling network, whereas histone deacetylase 2, a positive control, is located within the PI3K-AKT-mTOR signaling network, implying its regulation by this signaling network (Supporting Fig. S10B ). (13) Western blotting analysis with HCC cells treated with LY294002, a PI3K inhibitor, suggested that expression of BANF1, PLOD3, and SF3B4 may not commonly be regulated by PI3K signaling pathway (Supporting Fig. S10C,D) . Furthermore, we also noted that expression of an individual molecule does not effect on another molecule expression in HCC cells (Supporting Fig. S11 ).
BANF1 protein is a barrier-to-autointegration factor. It is a conserved human chromatin protein that is mainly involved in nuclear assembly and chromatin decondensation. (14) In vertebrates, procollagen-lysine hydroxylation is catalyzed by three lysyl hydroxylase isoenzymes (LHs) encoded by the genes for procollagen-lysine and 2-oxoglutarate 5-dioxygenase (PLOD). (15) PLOD3 (also known as LH3) is the only isoenzyme that generates hydroxylysine-linked carbohydrates because of its galactosyl-and glucosyl galactosyl-transferase activities, which are critical for procollagen intermolecular cross-linking and stabilization of fibrils into the supramolecular collagen structure. (16) Although it has not been studied much about BANF1 and PLOD3, studies have shown that BANF1 and PLOD3 also play a role in the development of cancer. For example, in HeLa cells, RNAiinduced down-regulation of BAF (BANF1) significantly increased the proportion of early S-phase cells that retained high levels of cyclin D3 and cyclin E expression and slowed progression through early S phase. (17) In addition, a recent report suggested that LH3 (PLOD3) might be involved in recruitment of matrix metalloproteinase 9, which plays a prominent role in extracellular matrix remodeling and transforming growth factor-beta activation. (18) SF3B4 encodes a core protein in the mammalian SF3b complex, which is part of the U2-type spliceosome that helps tether the U2 snRNP to the branch site. (19) A recent comprehensive analysis of HCC indicated that many spliceosome pathway-related genes, including SF3B4, are up-regulated in HCC and are associated with poor prognosis of HCC patients. (20, 21) However, no underlying mechanisms for enhanced SF3B4 expression and the consequences of its aberrant regulation have been suggested in cancer. In this study, we showed that SF3B4 was overexpressed in a large cohort of HCC patients, and this aberrant overexpression was significantly associated with poor prognosis of HCC patients (Fig. 5) . We also observed that SF3B4 knockdown caused G1/S cell-cycle arrest by recovering p27
Kip1 expression and simultaneously suppressing cyclins and cyclin-dependent kinases (CDKs) in HCC cells (Fig. 6B) . In addition, sustained suppression of SF3B4 reduced the in vivo tumor growth rate in a mouse xenograft model. Notably, SF3B4 knockdown increased alternative transcript splicing event in a large number of genes in HCC cells. From this, we demonstrated that SF3B4 inactivation recovered WT KLF4 transcript expression and thereby exerted an antitumor growth effect on HCC cells by directly modulating the negative cell-cycle protein, p27 Kip1 , and EMT protein, Slug (Fig. 7 A,B,D) . It is not clear whether SF3B4 overexpression leads to the epigenetic activation of cell-cycle proteins, such as CDKs, and cyclins, per se or if other processes also mediate this phenomenon. Nonetheless, the present study demonstrates that SF3B4 can modulate the expression of cell-cycle and EMT proteins through spliceosome activity on tumor suppressor KLF4 in HCC (Fig. 7F) .
The collective data presented here demonstrate that a panel composed of BANF1, PLOD3, and SF3B4 is very useful in distinguishing dysplastic from early malignant hepatocellular nodules arising in regenerating nodules. Targeted inactivation of these molecules inhibits in vitro and in vivo liver tumorigenesis by selectively modulating cell-cycle and EMT proteins in HCC cells. Furthermore, we demonstrate that SF3B4 functions as an early driver by inducing aberrant KLF4 splicing to produce nonfunctional SE transcripts in human HCG. Altogether, these findings implicate BANF1, PLOD3, and SF3B4 as diagnostic markers for early-stage HCC and suggest their potential therapeutic value for the treatment of HCC.
